Book an Appointment
Call +27 (0)11 718 3004
DMSO (dimethylsulfoxide) is another molecule that can be used to carry toxins into cancer cells because of its high affinity for cancer cells. The following facts regarding DMSO are relevant:
The great problem with chemotherapy drugs is that they do not specifically target cancer cells in the presence of normal cells, which explains the serious toxicity problem that goes with chemotherapy for cancer patients. This means that, as in the case of IPT, very much smaller doses of the drugs can be used with DMSO-PT with little or no side effects.
Tragically, these developments have been violently suppressed by the authorities. it is easy to see why. Using these methods, the amount of chemo therapy drugs sold would be reduced by 90%, a loss of billions of dollars to the industry.
DMSO as such may be of great value in the treatment of different types of cancer. It has been shown to promote differentiation of malignant bone marrow cells, and therefore may be of value in patients who require bone marrow transplants (107).
DMSO has also been shown to retard cancer of the bladder (108), colorectal cancer (109), ovarian cancer (110), breast cancer (111) and skin cancer (112).
DMSO stimulates various parts of the immune system and scavenges hydroxyl radicals, the most dangerous of all free radicals. It also increases the flow of essential minerals across cell membranes and may diminish the effects of carcinogens by cleansing cell membranes.
Increased percentage kill of adenocarcinoma breast cancer cells by various ntineoplastic agents has been demonstrated in tissue culture in the presence of DMSO (5-10%). This was demonstrated by Dr. Pommier and associates at the University of Portland (USA). (Am J Surg1988, 155 : 672). Dramatic results on patients with various cancers by chemotherapy drugs in the presence of 10 % DMSO were subsequently shown by Hauser et al. (Ibid., p 154). More than 90% objective remissions were seen in the case of lymphoma and breast cancer patients using low-dose chemotherapy in the presence of 10% DMSO, demonstrating the effect of DMSO in vivo.
According to Dr. Hauser et al. ( Ibid., p 153), DMSO appears to be particularly useful in the treatment of brain tumours and metastases because of the ease with which it crosses the blood-brain barrier.
Orally ingested DMSO was found to cause a twofold increase in the concentration of labelled cyclophosphamide in plasma, brain and liver tissues. The elevation persisted for about 2-3 hours, but subsequently returned to normal levels.
Similar effects are seen in humans. Typically in one experiment instead of giving 2000mg of cyclophosphamide, only 150-200mg was given per dose. This is similar to the doses used in IPT.
Remarkable results were obtained with breast cancer patients: 13 of 15 inoperable breast cancer patients with metastases were induced to remission with the DMSO-cyclophosphamide protocol. Of 65 other patients, 44 achieved remission. No side-effects were seen and pain was relieved to such an extent that no morphine was required (Ann New York Acad Sc 1975, 243: 412). Although these promising results were obtained more than 30 years ago, no adequate follow-up studies have been conducted to confirm these very promising results due to medical scepticism and behind the scenes financial interests.
From the work done by Dr. Hauser DMSO seems to have some specific advantage.
DMSO targets cancer cells and so transports the “primary medicine” into the cancer cells. This makes the medicine more effective.